Loading organizations...
BioSnap is a Brazil-based technology company that develops artificial intelligence-powered solutions for automating complex operational processes within sterile environments. The organization primarily serves the laboratory and pharmaceutical sectors by deploying advanced software systems designed to manage critical workflows in highly controlled settings. By integrating automation technology into these specialized research and manufacturing facilities, the platform aims to enhance operational efficiency and maintain strict regulatory compliance during sensitive procedures. Specific details regarding the company's overall financial scale, total venture funding raised, current market valuation, and exact employee headcount remain undisclosed in public market databases. Furthermore, the enterprise currently operates without publicly disclosing its core commercial business model, lead institutional investors, or a roster of recognizable enterprise customers. The exact founding year and the identities of the original founders are not currently available in standard corporate registries.
BioSnap has raised $20K across 1 funding round.
BioSnap has raised $20K in total across 1 funding round.
BioSnap has raised $20K in total across 1 funding round.
BioSnap's investors include Parallel18.
BioSnap has raised $20K across 1 funding round. Most recently, it raised $20K Seed in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2024 | $20K Seed | — | Parallel18 | Announced |
BioSnap refers to multiple entities in the biotech and automation space, with the most prominent being a technology company focused on AI-driven process automation in sterile environments, such as cleanrooms and pharmaceuticals.[1][4][6] It develops devices and integrated AI solutions to enhance clean room sampling, sterility testing, and automation, serving industries like research services, biopharma, and manufacturing.[1][4] This addresses challenges in contamination control and efficiency in sterile settings, with growth evidenced by specialized hardware like the BioSnap Telecentric Analyzer for high-precision bioassays (e.g., viral plaque assays, colony counting).[3] Other variants include a sustainable packaging project using biodegradable bioplastics with Easysnap technology for unit-dose sachets[2][8] and an AI-powered digital pathology platform for remote slide analysis, which raised ₹8 crore in seed funding.[5]
BioSnap's core technology company emerged to tackle inefficiencies in sterile process automation, leveraging AI integration for cleanroom devices, though specific founding year and founders are not detailed in available sources.[1][4][6] The Brazilian entity (biosnap.com.br) positions itself as an innovator in sterile environments, likely building on global biotech needs post-pandemic.[6] Parallel projects like the EU-funded BIOSNAP initiative originated from Proplast and Easysnap Machinery to extend patented snap-open technology into eco-friendly PHA/PLA bioplastic packaging, aiming for sustainable unit-dose solutions compliant with EU plastic reduction directives.[2][8] In imaging, the BioSnap Telecentric Analyzer from ImmunoSpot evolved for versatile bioassays in petri dishes and well plates.[3] The Indian BioSnap spun out to advance AI digital pathology, securing early seed investment for remote diagnostics.[5] Pivotal traction includes specialized hardware adoption and funding for pathology AI.
BioSnap rides the wave of AI-biotech convergence in sterile manufacturing and diagnostics, fueled by post-2020 demand for contamination-free automation in pharma and cleanrooms amid regulatory pressures like EU plastic bans.[1][2][6][8] Timing aligns with biopharma's shift to high-throughput assays and sustainable packaging, where market forces favor AI tools reducing manual errors in viral testing and pathology—critical for vaccine development and personalized medicine.[3][5] It influences the ecosystem by enabling faster R&D cycles, from microbial sterility checks to eco-packaging, supporting broader trends in green biotech and telehealth amid labor shortages in sterile ops.
BioSnap is poised to expand AI-sterile tech amid rising cleanroom demands, potentially integrating pathology AI with automation hardware for end-to-end biopharma workflows.[1][3][5][6] Trends like EU sustainability mandates and AI assay acceleration will propel growth, with the packaging arm scaling biodegradable innovations globally.[2][8] Its influence may evolve toward full-stack sterile AI platforms, consolidating fragmented tools—watch for partnerships in high-throughput biomanufacturing to dominate precision biotech. This positions BioSnap as a key enabler in resilient, green supply chains, echoing its mission to transform sterile processes.[1]
